Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Net Income (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Net Income for 4 consecutive years, with -$21.1 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 71.62% to -$21.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$221.1 million through Dec 2025, up 33.88% year-over-year, with the annual reading at -$221.1 million for FY2025, 33.88% up from the prior year.
  • Net Income for Q4 2025 was -$21.1 million at Phathom Pharmaceuticals, up from -$30.0 million in the prior quarter.
  • The five-year high for Net Income was -$21.1 million in Q4 2025, with the low at -$94.3 million in Q1 2025.
  • Average Net Income over 4 years is -$59.6 million, with a median of -$53.0 million recorded in 2022.
  • The sharpest move saw Net Income crashed 123.2% in 2024, then soared 71.62% in 2025.
  • Over 4 years, Net Income stood at -$55.0 million in 2022, then tumbled by 44.76% to -$79.6 million in 2023, then rose by 6.36% to -$74.5 million in 2024, then skyrocketed by 71.62% to -$21.1 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$21.1 million, -$30.0 million, and -$75.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.